Basic Information
Mondego Bio, headquartered in Portugal, and its main biotechnology park Biocant are developing a first-class protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitor, offering a potential immuno-oncology therapy with higher safety and tolerance.
Mondego Bio
Portugal
unclear
--
--
--
Enterprise Profile
Industrial Sector
Concept
Application Scenarios